CAP Dr. Vicens Papaceit
- Address
- Placa de L’era s/n, 08430 La Roca del Valles, Spain
CAP Dr. Vicens Papaceit - Cardiovascular Disease Prevention Research
CAP Dr. Vicens Papaceit is a primary care research center specializing in cardiovascular disease prevention and risk reduction strategies. The center focuses on innovative therapeutic approaches to prevent major adverse cardiovascular events in high-risk patient populations, particularly those without established cardiovascular disease.
- Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
- Novel lipid-lowering therapies and cardiovascular risk reduction
- Prevention of major adverse cardiovascular events (MACE) in high-risk populations
The center is actively involved in large-scale, multicenter clinical trials evaluating advanced interventions such as inclisiran for preventing composite cardiovascular outcomes including cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization. Their research emphasizes the critical importance of early intervention in patients at high cardiovascular risk before the development of established disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CAP Dr. Vicens Papaceit
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Inclisiran in Reducing Major Adverse Cardiovascular Events in High-Risk Primary Prevention of Atherosclerotic Cardiovascular Disease | Novartis Pharma AG | Phase III | Not Recruiting | Sep 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.